Is this the beginning of the AI-in-drug-discovery era, or the beginning of the end?

Taking stock of the drug industry, from the lab to the medicine chest

December 3, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | Opinion: Is this the beginning of the AI-in-drug-discovery era, or the beginning of the end? If what's past is prologue, then investors may follow disillusioned founders and leave the nexus of AI and drug discovery altogether. By Caleb Appleton STAT+ | Using AI to design small molecule drugs is tough. Here are five companies trying to crack the code Here are five startups trying to get AI models to design small-molecule drugs at a better hit rate than traditional experiments. By Brittany Trang Private Medicare insurers are likely to benefit in Trump's new administration The Medicare Advantage program is expected to cost taxpayers and beneficiaries more than $500 billion this year. By Bob Herman

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser